Comparative Pharmacology
Head-to-head clinical analysis: ALA SCALP versus BETATREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA SCALP versus BETATREX.
ALA-SCALP vs BETATREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (PpIX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), PpIX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.
Betamethasone is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and alter connective tissue response.
Topical application of a 5% solution to the scalp twice daily.
Adults: 1 gram intravenously every 24 hours. For severe infections, 1 gram every 12 hours may be used.
None Documented
None Documented
Not applicable; topical ALA-SCALP is not significantly absorbed systemically. After systemic absorption from photodynamic therapy, terminal half-life is approximately 1 hour due to rapid metabolism.
Terminal elimination half-life is 8-12 hours in adults with normal renal function, allowing twice-daily dosing.
Primarily renal elimination of metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion is negligible.
Renal elimination of unchanged drug accounts for approximately 60-70% of the dose; biliary excretion contributes about 20-25%, with the remainder eliminated via feces.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid